MONTREAL, Nov. 7, 2019 /CNW Telbec/ - Optina Diagnostics, a world leading company in retinal imaging and artificial intelligence with a vision to change mindsets when it comes to brain health, and Wagner Macula Retina Center, a center of excellence for ophthalmology, are entering into a collaboration agreement to conduct a clinical study for the advancement of Optina's Retinal Deep Phenotyping platform. This collaboration will lay the groundwork for Optina's future pivotal clinical trial.
"As we enter into Alzheimer's month, we are particularly excited at the opportunity to collaborate with Dr. Wagner, Dr. Kapoor, and the professional team at the Wagner Macula Retina Center. It brings together a whole new paradigm for the way we think about, how we diagnose and how we understand brain health and Alzheimer's. This is the first market readiness collaboration where Optina will deploy its exclusive eye clinic program & Retinal Deep Phenotyping platform in a community setting. It will prepare the ground for additional prime eye clinics locations across the United States to develop a brain health expertise" said David Lapointe, CEO at Optina Diagnostics.
"Most key opinion leaders agree that there is a need for earlier diagnosis when it comes to memory loss. Having the opportunity to participate in the final stages of Optina's platform development, and collaborating with a well-characterized patient cohort coming from prominent memory clinics in Virginia and North Carolina will allow Wagner Retina Macula Center to remain at the forefront of patient health care providing them with additional support and medical services when they need it the most" said Alan L. Wagner, M.D., F.A.C.S, F.I.C.S., A.M.E., Founder and President of Wagner Macula Retina Center.
Currently, it takes many years to find the causes of memory loss and cognitive impairment. According to the Alzheimer's Association, in the U.S. 82% of seniors say it's important to have their thinking or memory checked but only 16% say they receive regular cognitive assessments.1 A breakthrough technology like OptinaDx could help with early detection of Alzheimer's disease, the most common type of dementia, for proper patient management and prevention of irreversible brain damage. Thus, part of this clinical study, Wagner Macula Retina Center will be working in partnership with OptinaDx to capture the data-rich eye images of an at-risk population in a real-world setting.
About Optina Diagnostics
Optina Diagnostics is a Montreal-based company focused on changing mindsets when it comes to brain health. Optina's first application to detect amyloid status for the evaluation of adult patients with cognitive impairment, obtained FDA breakthrough designation earlier this year. Optina is also developing a broad pipeline of biomarkers. Through its unique Retinal Deep Phenotyping platform, Optina challenges the status quo by providing an accurate, simple, and non-invasive optical test to understand the sources of cognitive decline empowering millions. www.Optinadx.com
About Wagner Macula Retina Center
Wagner Macula Retina Center is internationally recognized for its pioneering approaches to scientific research, Lean Six Sigma, and care delivery to the underserved. Their "privademic" practice of medicine blends academics and research with hospitality and population health management enabling care to all members of the community at large.
Source: 2019 Alzheimer's Disease Facts And Figures https://www.alz.org/media/Documents/alzheimers-facts-and-figures-infographic-2019.pdf
SOURCE Optina Diagnostics
For further information: David Lapointe CEO, [email protected]